Agilon health Q4 net loss $230M, medical margin negative $102M; FY2024 guidance slashed

agilon health, inc.

Q4 revenue $1.06B (+72% YoY) but gross profit of negative $95M vs $16M a year ago.
Full-year 2023 net loss $263M vs $107M in 2022; Adjusted EBITDA loss $95M.
Medical margin for Q4 negative $102M; FY2023 $299M vs guidance midpoint $350M.
FY2024 medical margin guidance cut to $400-450M from prior $560-600M; Adj. EBITDA now loss of $60-15M vs prior profit $40-60M.
Class of 2025 adds at least 60K MA members across 5 physician groups; entry costs lowered to $55-65M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.96

agilon health, inc. reported the three and twelve months ended December 31, 2023 results: revenue Total revenue of $1.06 billion in the fourth quarter 2023 increased 72% compared to $615 million in the fourth quarter 2, net income Net loss of $230 million in the fourth quarter 2023 compared to a loss of $57 million in the fourth quarter 2022. For th. Guidance reaffirmed.

Period: the three and twelve months ended December 31, 2023
Revenue: Total revenue of $1.06 billion in the fourth quarter 2023 increased 72% compared to $615 million in the fourth quarter 2
Net income: Net loss of $230 million in the fourth quarter 2023 compared to a loss of $57 million in the fourth quarter 2022. For th
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On February 27, 2024 , agilon health, inc. (“agilon” or the “Company”), a Delaware corporation, issued a press release setting forth its financial results for the three and twelve months ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

agilon health, inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-007195

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.